Olipudase alfa

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sphingomyelin Lipidosis

Conditions

Sphingomyelin Lipidosis

Trial Timeline

May 1, 2015 → Dec 9, 2019

NCT ID

NCT02292654

About Olipudase alfa

Olipudase alfa is a phase 1/2 stage product being developed by Sanofi for Sphingomyelin Lipidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02292654. Target conditions include Sphingomyelin Lipidosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06192576	Pre-clinical	Recruiting	Apr 16, 2024	Jan 15, 2029	Niemann-Pick Diseases
NCT05359276	Pre-clinical	Completed	Jun 10, 2022	Dec 31, 2024	Acid Sphingomyelinase Deficiency (ASMD)
NCT06949358	Phase 2	Completed	Nov 18, 2021	Apr 8, 2025	Niemann-Pick Disease
NCT02292654	Phase 1/2	Completed	May 1, 2015	Dec 9, 2019	Sphingomyelin Lipidosis

Competing Products

6 competing products in Sphingomyelin Lipidosis

See all competitors

Product	Company	Stage	Hype Score
Recombinant human acid sphingomyelinase	Sanofi	Phase 1	29
Olipudase alfa	Sanofi	Pre-clinical	26
placebo (saline) + Olipudase alfa	Sanofi	Phase 2/3	38
GZ402665	Sanofi	Phase 2	35
olipudase alfa (GZ402665)	Sanofi	Pre-clinical	26
rhASM + rhASM + rhASM + rhASM + rhASM	Sanofi	Phase 1	21